Loss of muscle mass and function occurs in various diseases. Myostatin blocking can
attenuate muscle loss, but downstream signaling is not well known. Therefore, to elucidate …

The congenital myopathies are a diverse group of genetic skeletal muscle diseases, which
typically present at birth or in early infancy. There are multiple modes of inheritance and …

Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …

Myogenic differentiation proceeds through a highly coordinated cascade of gene activation
that necessitates epigenomic changes in chromatin structure. Using a screen of small …

Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass
and strength that occurs with aging or in association with various diseases. The condition is …

Duchenne's muscular dystrophy is an X-linked neuromuscular disease that manifests as
muscle atrophy and cardiomyopathy in young boys. However, a considerable percentage of …

Muscle wasting, ie, cachexia, frequently occurs in cancer and associates with poor
prognosis and increased morbidity and mortality. Anticancer treatments have also been …

The past 18 months have seen a strong increase in the number of exciting reports on novel
therapeutic agents for DMD. Exon-skipping agents have been fine-tuned to improve tissue …

The extracellular matrix (ECM) plays key roles in normal and diseased skeletal and cardiac
muscle. In healthy muscle the ECM is essential for transmitting contractile force, maintaining …

The congenital myopathies–including Central Core Disease (CCD), Multi-minicore Disease
(MmD), Centronuclear Myopathy (CNM), Nemaline Myopathy (NM) and Congenital Fibre …